Substituted triazole derivatives as oxytocin antagonists

A compound of formula (I)

• wherein
• U, V, W and Z are each independently N or CR7;
• Y is N or CH;
• X is O or NR;
• R1 is selected from (i) phenyl, which is optionally substituted by one or more groups each independently selected from halo, hydroxy, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, COR9, CO2R9, NR9R10 and CONR9R10, (ii) a five to seven membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, which is optionally substituted by one or more groups independently selected from halo, hydroxy, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, COR9, CO2R9, NR9R10 and CONR9R10, and (iii) (C1-C6)alkoxy, which is optionally substituted by one or more substituents each independently selected from (C1-C6)alkoxy, halo, hydroxy and phenyl;
• R2 is hydrogen, halo, hydroxy, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, COR9, CO2R9, NR9R10 or CONR9R10;
• R3, R4, R5, and R6 are each independently hydrogen or (C1-C6)alkyl;
• R7 is independently selected from hydrogen, halo, hydroxy, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, COR9, CO2R9, NR9R10 or CONR9R10;
• R8 is hydrogen or (C1-C6)alkyl, CO(C1-C6)alkyl, CO2(C1-C6)alkyl or SO2(C1-C6)alkyl, each of which is optionally substituted by one or more groups independently selected from halo, hydroxy, (C1-C6)alkoxy, CN, NO2 and phenyl;
• and
• R9 and R10 are each independently hydrogen or (C1-C6)alkyl;
• a tautomer thereof or a pharmaceutically acceptable salt or solvate of said compound or tautomer thereof.